Carl Gordon returns to the Midas List for his second appearance thanks to a robust market for biotech buyouts and IPOs. Gordon invested in Seragon Pharmaceuticals' Series A in 2013 and a year later Swiss drugmaker Roche Group said it would acquire the breast cancer drugmaker for up to $1.7 billion. His other big deals of late include cancer drugmaker Aragon Pharmaceuticals (acquired by Johnson & Johnson for up to $1 billion in 2013), Acceleron Pharma (IPO 2013), hepatitis C drugmaker Inhibitex (acquired by Bristol-Myers Squibb for $2.5 billion in 2012) and in-demand antibody developer Adimab. Gordon, a Ph.D. in molecular biology from MIT and a chartered financial analyst, helped start OrbiMed's venture business in 2000. OrbiMed has since grown into the world's largest life sciences-dedicated investment firm.

Biotechnology, Venture Capital, Corporate Finance, Technology, Information Technology Business of Healthcare, Healthcare, Entrepreneurship, Finance,